Identifying prognostic and predictive value of mutations associated with clinical outcomes in first line (1L) patients with advanced or metastatic non-small cell lung cancer (aNSCLC).

被引：0
|
作者：
Perez Parente, Diego
Cobo-Dols, Manuel
Hasan, Haroon
Olson, Sara
Pal, Navdeep
Wilkinson, Samantha
La Orden Tevar, Beatriz
Perez Fernandez, Mar
Provencio-Pulla, Mariano
机构：
[1] Roche Farma, Lung Canc Squad, Madrid, Spain
[2] Hosp Univ Reg Malaga, Malaga, Spain
[3] Genentech Inc, Product Dev Data Sci, San Francisco, CA USA
[4] Roche Prod Ltd, Welwyn Garden City, Herts, England
[5] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9047
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?
    Yakup Bozkaya
    Osman Köstek
    Abdullah Sakin
    Deniz Tataroğlu Özyükseler
    Teoman Şakalar
    İbrahim Çil
    Supportive Care in Cancer, 2020, 28 : 2273 - 2282
  • [22] ECONOMIC IMPACT OF FIRST-LINE (1L) IMMUNOTHERAPIES IN ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Sarri, G.
    Freitag, A.
    Kazmierska, P.
    Lin, B.
    Pawar, V
    Zhang, X.
    VALUE IN HEALTH, 2020, 23 : S443 - S444
  • [23] Predictive score using clinical and blood biomarkers in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy
    Prelaj, A.
    Rebuzzi, S. E.
    Pizzutilo, P.
    Montrone, M.
    Pesola, F.
    Longo, V.
    Lapadula, V.
    Cassano, F.
    Petrillo, P.
    Bafunno, D.
    Varesano, N.
    Lamorgese, V.
    Mastrandrea, A.
    Ricci, D.
    Catino, A.
    Domenico, G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer
    Califano, Raffaele
    Landi, Lorenza
    Cappuzzo, Federico
    DRUGS, 2012, 72 : 28 - 36
  • [25] Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer
    Raffaele Califano
    Lorenza Landi
    Federico Cappuzzo
    Drugs, 2012, 72 : 28 - 36
  • [26] HEALTHCARE COSTS AND RESOURCE UTILIZATION IN 1L MAINTENANCE (1L MT) TREATMENT (TX) OF ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A SYSTEMATIC LITERATURE REVIEW
    Heldt, D.
    Snedecor, Sj
    Kalilani, L.
    Giove, Tj
    Aziez, A.
    Spoorendonk, Ja
    Shree, A.
    Rekowska, D.
    Stojadinovic, A.
    Hogea, C.
    VALUE IN HEALTH, 2022, 25 (01) : S98 - S99
  • [27] Prognostic and predictive value of HURP in non-small cell lung cancer
    Wang, Qi
    Chen, Yaokun
    Feng, Hui
    Zhang, Biyuan
    Wang, Haiji
    ONCOLOGY REPORTS, 2018, 39 (04) : 1682 - 1692
  • [28] Predictive and prognostic value of serum periostin in advanced non-small cell lung cancer patients receiving chemotherapy
    Zhang, Yan
    Yuan, Dongmei
    Yao, Yanwen
    Sun, Wenkui
    Shi, Yi
    Su, Xin
    TUMOR BIOLOGY, 2017, 39 (05)
  • [29] Predictive and prognostic value of de novo MET expression in patients with advanced non-small cell lung cancer
    Li, A.
    Niu, Y. F.
    Yang, J. J.
    Zhang, C. X.
    Zhou, Q.
    Su, J.
    Xie, Z.
    Lou, N. -N.
    Wen-Zhao, Z.
    Tu, H. -Y.
    Zhao, N.
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2015, 26 : 144 - 144
  • [30] Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients
    Boros, Angela
    Lacroix, Ludovic
    Lacas, Benjamin
    Adam, Julien
    Pignon, Jean-Pierre
    Caramella, Caroline
    Planchard, David
    de Montpreville, Vincent
    Deutsch, Eric
    Levy, Antonin
    Besse, Benjamin
    Le Pechoux, Cecile
    ONCOTARGET, 2017, 8 (15) : 25189 - 25199
12345